Hydralazine HCl , ≥99% , 304-20-1
Synonym(s):
1-Hydrazinophthalazine hydrochloride;Hydralazine hydrochloride
CAS NO.:304-20-1
Empirical Formula: C8H9ClN4
Molecular Weight: 196.64
MDL number: MFCD00135998
EINECS: 206-151-0
| Pack Size | Price | Stock | Quantity |
| 1g | RMB45.60 | In Stock |
|
| 5G | RMB148.00 | In Stock |
|
| 25G | RMB554.40 | In Stock |
|
| 100G | RMB1599.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 273°C |
| Boiling point: | 322.13°C (rough estimate) |
| Density | 1.2961 (rough estimate) |
| refractive index | 1.6110 (estimate) |
| storage temp. | 2-8°C |
| solubility | Soluble in water, slightly soluble in ethanol (96 per cent), very slightly soluble in methylene chloride |
| form | Solid |
| color | White to Almost white |
| PH | pH (20g/l, 25℃) : 3.5~4.5 |
| biological source | synthetic (organic) |
| Water Solubility | Soluble in water. Slightly soluble in diethyl ether and alcohol. |
| Merck | 14,4763 |
| BRN | 3568329 |
| BCS Class | 3 |
| Stability: | Stable. Incompatible with strong oxidizing agents. |
| InChIKey | ZUXNZUWOTSUBMN-UHFFFAOYSA-N |
| CAS DataBase Reference | 304-20-1(CAS DataBase Reference) |
| EPA Substance Registry System | 1(2H)-Phthalazinone, hydrazone, monohydrochloride (304-20-1) |
Description and Uses
Hydralazine is an orally bioavailable vasodilator and antihypertensive agent. It decreases DNA methylation in Jurkat cells at a concentration of 10 μM and inhibits extracellular and intracellular production of reactive oxygen species (ROS) in rat macrophages activated by phorbol 12-myristate 13-acetate (PMA; ) at a concentration of 100 μM. Hydralazine (100 μM) also decreases nitric oxide production and mRNA expression of inducible nitric oxide synthase (iNOS) in rat macrophages activated by LPS (Item Nos. 19660| 19661| 19662) and interferon-γ (IFN-γ). It reduces contraction of rat aortic arterial strips induced by potassium and norepinephrine (; IC50s = 2.2 and 3.06 mM, respectively). Hydralazine (2.6 mg/kg) lowers mean arterial blood pressure (MAP) by 41.76% in conscious rats. Formulations containing hydralazine have been used in the treatment of high blood pressure and heart failure.
Hydralazine is a non-nucleoside analog that inhibits DNA methylation and reactivates the expression of tumor suppressor genes. Non-selective MAO-A/B inhibitor; semicarbazide-sensitive amine oxidase inhibitor. Antihypertensive.
Safety
| Symbol(GHS) | ![]() GHS06 |
| Signal word | Danger |
| Hazard statements | H301-H315-H319-H335 |
| Precautionary statements | P301+P330+P331+P310-P305+P351+P338 |
| Hazard Codes | Xn |
| Risk Statements | 22-36/37/38 |
| Safety Statements | 26-36/37/39-45 |
| RIDADR | UN 2811 6.1/PG 3 |
| WGK Germany | 3 |
| RTECS | TH9000000 |
| TSCA | Yes |
| HazardClass | 6.1 |
| PackingGroup | III |
| HS Code | 29339900 |
| Hazardous Substances Data | 304-20-1(Hazardous Substances Data) |
| Toxicity | LD50 oral in rat: 280mg/kg |



![1,8-Diazabicyclo[5.4.0]undec-7-ene](https://img.chemicalbook.com/CAS/GIF/6674-22-2.gif)


